AstraZeneca submit European application for Seroquel XR in the treatment of Major Depressive Disorder « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

AstraZeneca submit European application for Seroquel XR in the treatment of Major Depressive Disorder

Posted on June 10, 2008 by crimsoncanary

AstraZeneca have submitted a European application for Seroquel (quetiapine fumarate) extended release Tablets for the treatment of major depressive disorder

Filed under: gpcr | Tagged: 5-HT2, 5HT2, antagonist, Astellas, Astrazeneca, Dopamine D2, quetiapine, Seroquel

« Metabasis present data on glucagon antagonist MB07803 at ADA Roches GLP-1 Taspoglutide moves into phase III »

Leave a Reply